Related Experiment Videos
Permeability factors in focal segmental glomerulosclerosis.
Virginia J Savin1, Ellen T McCarthy, Mukut Sharma
1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. vsavin@mcw.edu
Seminars in Nephrology
|April 22, 2003
Summary
Focal segmental glomerulosclerosis (FSGS) involves a permeability factor in patient plasma that causes kidney damage. This factor, carried by proteins/peptides, can be blocked by certain agents, offering hope for new FSGS therapies.
Area of Science:
- Nephrology
- Pathology
- Biochemistry
Background:
- Focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and kidney failure.
- FSGS incidence is rising, with unknown etiology in most cases.
- Post-transplant recurrence rates for FSGS range from 30% to 50%.
Purpose of the Study:
- To investigate the FSGS permeability factor hypothesis.
- To characterize the nature of the FSGS permeability factor.
- To explore potential therapeutic strategies targeting the FSGS permeability factor.
Main Methods:
- Functional assays measuring albumin permeability (P(alb)) and glomerular volume variation (GVV) in rats injected with patient plasma.
- Plasmapheresis and immunoadsorption to reduce permeability activity.
- In vitro studies using pharmacologic agents to block permeability activity.
Main Results:
- Patient plasma contains a factor that increases glomerular capillary permeability and causes proteinuria.
- This permeability activity is associated with post-transplant FSGS recurrence and rapidly progressive disease.
- The factor is carried by small, glycosylated, hydrophobic proteins/peptides and can be blocked by normal plasma components and certain drugs.
Conclusions:
- The FSGS permeability factor is a key driver of proteinuria and renal damage.
- Blocking this factor offers a promising therapeutic avenue for FSGS.
- Further research is needed to identify the factor and develop targeted interventions.